Trial Profile
Treatment of Stage IV Breast Cancer With OKT3 x Herceptin Armed Activated T Cells, Low Dose IL-2, And GM-CSF (Phase I Only as of 4-22-09 as Per IRB Approval Date)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Activated T cells (Primary) ; Aldesleukin (Primary) ; Interleukin-2 (Primary) ; Sargramostim (Primary)
- Indications Breast cancer; Ductal carcinoma
- Focus Adverse reactions; Therapeutic Use
- 09 Aug 2011 New trial record